Navigation Links
Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
Date:11/6/2008

SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, endocrinology, oncology, and dermatology markets, today reported financial results for the three and nine months ended September 30, 2008.

"The fundamentals for Halozyme have never been stronger and I am pleased with the initiation of our Phase 2 insulin clinical trial. The study will test our proprietary rHuPH20 hyaluronidase enzyme with two commercially available insulins in diabetic patients," stated Jonathan Lim, M.D., President and CEO of Halozyme. "Other Halozyme clinical programs are also moving forward expeditiously and Phase 1 studies in our bisphosphonate and PEGPH20 programs should be starting soon. Our five proprietary programs focus on the development of first-in-class or best-in-class compounds that target large commercial markets and the initiation of additional human clinical studies should enhance the value of our pipeline and drive shareholder returns."

Recent Corporate and Scientific Achievements

-- A Phase 2 insulin clinical trial has been initiated in Type 1 diabetic patients that will compare glycemic control of a standardized liquid meal challenge and insulin pharmacokinetics after administration of each of four dosing regimens: Humulin(R) R (regular insulin human) with and without rHuPH20 and Humalog(R) (insulin lispro) with and without rHuPH20. The study is designed to detect faster absorption and a more rapid onset of action for both types of insulin when given in combination with Halozyme's rHuPH20 enzyme. Results should be available in mid-2009.

-- A clinical study in bladd
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
2. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics to Host Research Day for Investors and Analysts
5. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4